alexa Benefits Of The Nephros Dual Stage Ultra-filter In Chronic Hemodialysis Patients: Evidence For Improved ESA Responsiveness
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

11th International Conference on Nephrology & Urology
March 22-23, 2017 Rome, Italy

Ronald Villota
New York Presbyterian Hospital-Columbia University Medical Center, USA
ScientificTracks Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959.C1.036
Ultrapure dialysate has been shown to reduce inflammatory markers and improve nutritional and anemia parameters in patients on chronic maintenance hemodialysis. The DSU (dual stage ultra-filter) has been shown to reduce bacterial counts and endotoxin levels by at least a 5-log order of magnitude. We performed an observational trial of this filter in a hospital-based acute dialysis facility in the USA. There were 23 chronic stable hemodialysis outpatients at New York Presbyterian Hospital–Columbia University Medical Center treated during the six months after the installation of the DSU filters. The mean age was 51 (range 12-91), 61% male, predominantly hispanic (70% hispanic, 17% African-American, 9% Caucasian and 4% Asian) and 30% diabetic. Comparing data from the six months period after the installation of the filters to the preceding six months, there was an increase in the mean hemoglobin level of 0.5 g/dL (p=0.010) with a reduction in the mean weekly darbepoetin dose of 14.6 mcg (P<0.001) translating to a reduction in the ESA resistance index (weekly ESA dose/hemoglobin level) of 1.52 (p<0.001). During this time period, indirect inflammatory markers showed a reduction in the mean WBC count of 0.46 (p=0.008), an increase in serum albumin of 0.08 (p=0.024), an increase in the TSAT of 1.0% (p=0.34, NS) and an increase in the serum ferritin of 85 (p=0.06). In conclusion, the use of a filter to further reduce endotoxin exposure in chronic hemodialysis patients can result in improved ESA responsiveness and a lower ESA dose.


image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version